RAW DATA (part I) of "Sweetener Substitutes Circumvented Metabolic dysfunction-Associated

**RAW DATA (part I) of "Sweetener Substitutes Circumvented Metabolic dysfunction-Associated **
Zhe Cheng — 2026-06-14T10:19:29Z · Open Access
figshare.32220486 · Figshare

TL;DR — A 17.45 GB supplementary data deposit (figshare.32220486, 12 file(s), liver) in the MASLD / NAFLD / NASH data lake. under-mined portal (Figshare).


0. Summary

Biological premise.

The following premise is sourced from the repository record (not fabricated).

Background: Epidemiological evidence consistently indicates that the risk of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and hepatic fibrosis associated with sweetener substitutes is markedly lower than that of traditional sweeteners. However, the mechanisms by which sweetener substitutes circumvent remain largely unexplored.

Objective: To systematically elucidate the key mechanism underlying the protective effects of sweetener substitutes against sweetener-induced MASLD and hepatic fibrosis.

Methods: Chemical structures were retrieved from pubChem, followed by target prediction and screening to identify the unique risky targets exclusively mediated by sweeteners. Disease targets were collected and intersected with the aforementioned risky targets for comprehensive network toxicological analysis. Molecular docking was performed to verify the binding affinity. Expression profiles of these targets in clinical specimens were analyzed using the GEO and HPA databases. A mouse model of MASLD with hepatic fibrosis was established, while hepatic transcriptome sequencing was applied to validate in vivo target expression patterns. In vitro models were constructed using steatotic HepG2 cells and activated LX-2 cells. Oil Red O staining, immunofluorescence, and RT-qPCR were employed to verify the abrogating effects of sweetener substitutes on sweetener-mediated aberrant target expression and cellular injury.

Results: A total of 111 risky targets specific to sweeteners were identified, among which 31 were associated with MASLD and 54 with hepatic fibrosis. Enrichment analysis revealed that the AMPK pathway, centered on FOXO1, SREBF1, and SCD, was the core cascade through which sweetener substitutes mitigate MASLD risk, while the growth hormone synthesis, secretion and action pathway, dominated by ITPR1 and SSTR2, was responsible for reducing hepatic fibrosis risk. Clinical database analysis, consistent with the mouse model, showed dysregulated expression of FOXO1 and SREBF1 in liver tissues of MASLD individuals, as well as that of ITPR1 and SSTR2 with increasing fibrosis severity. In vitro experiments demonstrated that sweeteners induced lipid accumulation in HepG2 cells, downregulated FOXO1, upregulated SREBF1, and activated LX-2 cells with enhanced ITPR1 and SSTR2 expression. In contrast, the main sweetener substitutes reversed these abnormalities.

Every file in this dataset is a supplementary data readout relevant to MASLD / non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatohepatitis (NASH), landed from Figshare.

Assay and processing.

Modality: supplementary data (repository subtype: supp-data). Tier-1 (must-have) for this modality = the processed tables behind the paper's claims + a sample/condition key; Tier-2 (recommended) = author analysis tables, annotation, code; Tier-3 (optional / raw) = raw signal underlying the processed tables. The Completeness line in each dataset block below states, measured from the landed files, which tiers are present.

Sources.

  • figshare.32220486 — Figshare deposit (under-mined portal (Figshare)).
  • PMIDs: none recorded in the index for this deposit.
DiseaseMASLD / NAFLD / NASH
Assay / modalitysupplementary data — supp-data
Organismsunspecified
RepositoryFigshare
Accessionfigshare.32220486
AccessPublic (open); files mirrored in this dataset's input/ folder.
Number of studies1
Number of files12
Total size17,450,149,504 bytes (≈ 17.45 GB)
LicenseCC BY 4.0

1. Datasets — sample sources, protocols, experiment design and metadata

Landed sources at a glance.

SourceAccessFiles
Figsharepublic / OPEN-processed12

The deposit at a glance.

AccessionDescriptionOrganismSamplesScale
figshare.32220486under-mined portal (Figshare)unspecifiedn/a12 files · 17.45 GB

figshare.32220486 — RAW DATA (part I) of "Sweetener Substitutes Circumvented Metabolic dysfunction-Associated

Figshare record · 12 files · 17.45 GB

  • Sample source. unspecified material; MASLD/NAFLD/NASH context (under-mined portal (Figshare)).

  • Samples and retention. Sample count not declared in the repository index; see the per-sample metadata file(s) listed below.

  • Experiment design. Repository subtype: supp-data; disease context MASLD/NAFLD/NASH.

  • Metadata available. See the annotated file table below; per-sample metadata ships in the ISA-Tab / SDRF / metadata file(s) where present.

  • Files (annotated).

    FileWhat it is
    JZ25100532-N_B_N5526-03-Poly-A1_N_B-N_B_N5526-03-Poly-A1_N_B_combined_R2.fastq.gzData file
    JZ25100533-N_B_N5526-04-Poly-A2_N_B-N_B_N5526-04-Poly-A2_N_B_combined_R1.fastq.gzData file
    JZ25100533-N_B_N5526-04-Poly-A2_N_B-N_B_N5526-04-Poly-A2_N_B_combined_R2.fastq.gzData file
    JZ25100535-N_B_N5526-06-Poly-A5_N_B-N_B_N5526-06-Poly-A5_N_B_combined_R2.fastq.gzData file
    JZ25100532-N_B_N5526-03-Poly-A1_N_B-N_B_N5526-03-Poly-A1_N_B_combined_R1.fastq.gzData file
    JZ25100533-N_B_N5526-04-Poly-A2_N_B-N_B_N5526-04-Poly-A2_N_B_combined_R1.fastq.gz.md5Data file
    JZ25100532-N_B_N5526-03-Poly-A1_N_B-N_B_N5526-03-Poly-A1_N_B_combined_R2.fastq.gz.md5Data file
    JZ25100533-N_B_N5526-04-Poly-A2_N_B-N_B_N5526-04-Poly-A2_N_B_combined_R2.fastq.gz.md5Data file
    JZ25100535-N_B_N5526-06-Poly-A5_N_B-N_B_N5526-06-Poly-A5_N_B_combined_R1.fastq.gz.md5Data file
    JZ25100535-N_B_N5526-06-Poly-A5_N_B-N_B_N5526-06-Poly-A5_N_B_combined_R2.fastq.gz.md5Data file
    JZ25100535-N_B_N5526-06-Poly-A5_N_B-N_B_N5526-06-Poly-A5_N_B_combined_R1.fastq.gzData file
    JZ25100532-N_B_N5526-03-Poly-A1_N_B-N_B_N5526-03-Poly-A1_N_B_combined_R1.fastq.gz.md5Data file
  • How this experiment became a dataset. figshare.32220486 resolved via the Figshare record API → 12 open file(s) fetched into this dataset's input/ folder → sizes verified on disk (17,450,149,504 bytes (≈ 17.45 GB)).

  • Completeness (supplementary data). Present: primary data table(s). (Tiers per the matching modality skill; assessment measured from landed filenames/headers.)


2. Analyses this atlas supports

  • Reuse the processed tables. Start from JZ25100532-N_B_N5526-03-Poly-A1_N_B-N_B_N5526-03-Poly-A1_N_B_combined_R2.fastq.gz; combine with the per-sample metadata file to reproduce the deposit's headline numbers.
  • Cross-cohort MASLD integration. Combine this deposit (figshare.32220486) with other liver/MASLD datasets in the lake sharing the same modality for meta-analysis.

Reproduce. All files are in this dataset's input/ folder; the source of record is figshare.32220486 (https://figshare.com/articles/dataset/_/32220486). Re-fetch with the MASLD crawler (masld_download_pass.py --only figshare.32220486); sizes are verified on disk and recorded in this dataset's metadata.json.


Citation

Zhe Cheng. *RAW DATA (part I) of "Sweetener Substitutes Circumvented Metabolic dysfunction-Associated *. Figshare accession figshare.32220486. https://doi.org/10.6084/m9.figshare.32220486.v1

About this dataset

This 10x Genomics dataset provides single-cell gene expression from liver samples, with disease state recorded as MASLD/NAFLD/NASH.

Analyze it in Drylab

Open this dataset in Drylab and ask a question in plain language. The AI agent loads the files, runs the analysis in a ready sandbox and explains each result. A typical first pass:

  1. Load the filtered feature-barcode matrix (HDF5) and run quality control on counts, genes and mitochondrial reads per cell.
  2. Normalize, select variable genes, then cluster the cells and draw a UMAP.
  3. Annotate clusters with marker genes and compare the cell-type mix between conditions.
  4. Run differential expression between cell types or samples to characterize masld/nafld/nash biology.